Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of ligelizumab in chronic spontaneous urticaria after prior ligelizumab/omalizumab studies
MOH_2020-05-24_008903Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of ligelizumab in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis. Started May 2020; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on MOH_2020-05-24_008903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-24_008903.